Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Rule of Six

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44294   clinical trials with a EudraCT protocol, of which   7351   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    32 result(s) found for: Rule of Six. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2013-001838-17 Sponsor Protocol Number: MV140-SLG-003 Start Date*: 2015-07-17
    Sponsor Name:Inmunotek, S.L. [...]
    1. Inmunotek, S.L.
    2. INMUNOTEK, S.L.
    Full Title: PROSPECTIVE MULTICENTER CLINICAL TRIAL RANDOMIZED, DOUBLE-BLIND, PARALLEL-CONTROLLED VERSUS PLACEBO IN A POLYVALENT SUBLINGUAL BACTERIAL VACCINE (IN ORAL MUCOSA) TO THREE MONTHS AND SIX MONTHS IN ...
    Medical condition: Recurrent Urinary Tract Infections
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004862 10038140 Recurrent urinary tract infection LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2009-016678-34 Sponsor Protocol Number: CRO1456 Start Date*: 2010-04-15
    Sponsor Name:Imperial College London
    Full Title: Exploring the Relationship Between Insulin Resistance and Interferon Resistance: Options to Overcome HCV Non-Response to Pegylated Interferon
    Medical condition: HCV infected patient who do not response to Pegylated Interferon. This study is trying to explore the relationship between insulin resistance and Interferon Resistance and the possible rule of Pio...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2022-001522-30 Sponsor Protocol Number: RIMOFATSCI-2 Start Date*: 2022-10-03
    Sponsor Name:Fundación Hospital Nacional de Parapléjicos
    Full Title: Effects of a CB1 receptor reverse antagonist/agonist (Rimonabant) on wandering ability in patients with incomplete spinal cord injuries
    Medical condition: Possibility of improving wandering in patients. The effects of Rimonabant on other functional measures will be assessed and it will be confirmed that it is a safe treatment in the study population.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002011-33 Sponsor Protocol Number: PROGRESS Start Date*: 2017-08-28
    Sponsor Name:Hellenic Institute for the Study of Sepsis
    Full Title: A RANDOMIZED PROSPECTIVE CLINICAL TRIAL TO ASSESS THE ROLE OF PROCALCITONIN-GUIDED ANTIMICROBIAL THERAPY TO REDUCE LONG-TERM INFECTIONS SEQUELAE
    Medical condition: USE OF PROCALCITONIN IN EARLY STOP OF ANTIBIOTICS TO AVOID LONG-TERM CONSEQUENCES
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10040047 Sepsis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2019-002511-26 Sponsor Protocol Number: 08062019 Start Date*: 2019-12-20
    Sponsor Name:Rigshospitalet
    Full Title: Repeated Injection Therapy of Allogeneic Stem Cells in Ischemic No-option Patients - A Multi-Centre Study (SCIENCE REPEAT)
    Medical condition: Ischemic heart failure
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10019285 Heart failure, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-000870-63 Sponsor Protocol Number: WV19432 Start Date*: 2007-03-01
    Sponsor Name:F.Hoffmann-La Roche Ltd
    Full Title: A phase IV, 2x2 factorial, double blind study of 24 versus 48 weeks and 90 versus 180 mcg doses of pegylated interferon alfa 2a 40KD (PEG IFN, Ro 25-8310) in adult patients with HBeAg positive chro...
    Medical condition: Chronic hepatitis B
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008910 Chronic hepatitis B LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-004823-39 Sponsor Protocol Number: CC-5013-MM-020/IFM 07-01 Start Date*: 2008-04-03
    Sponsor Name:Celgene Corporation
    Full Title: A PHASE III, RANDOMIZED, OPEN-LABEL, 3-ARM STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LENALIDOMIDE (REVLIMID) PLUS LOW-DOSE DEXAMETHASONE WHEN GIVEN UNTIL PROGRESSIVE DISEASE OR FOR 18 FOUR-WEEK...
    Medical condition: Previously untreated multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (Completed) IE (Prematurely Ended) IT (Completed) AT (Completed) ES (Completed) SE (Completed) BE (Completed) PT (Completed) DE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2009-014815-11 Sponsor Protocol Number: E6201-E044-204 Start Date*: 2010-03-10
    Sponsor Name:Eisai Limited
    Full Title: A 12-Day Randomized, Blinded, Vehicle and Active Comparator-Controlled Study to Determine the Efficacy and Safety of Six Concentrations of Topical E6201 Gel in Subjects with Psoriasis Vulgaris
    Medical condition: Chronic stable plaque psoriasis with one or two stable psoriatic plaque(s) suitable in size and location for five separate treatment fields to be assessed within it.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-019884-12 Sponsor Protocol Number: INFIRE-001 Start Date*: 2010-12-17
    Sponsor Name:Universitätsklinikum Aachen
    Full Title: Induction of Fibrosis Regression regarding Chronic Hepatitis B Infection
    Medical condition: Patients with chronic hepatitis B infection and a relevant grade of fibrosis (histological >= F2)
    Disease: Version SOC Term Classification Code Term Level
    15.0 10021881 - Infections and infestations 10008910 Chronic hepatitis B LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-004743-22 Sponsor Protocol Number: FFR30006 Start Date*: Information not available in EudraCT
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mc...
    Medical condition: Vasomotor/Idiopathic Rhinitis
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) CZ (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-004744-43 Sponsor Protocol Number: FFR30007 Start Date*: Information not available in EudraCT
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mc...
    Medical condition: Vasomotor/Idiopathic Rhinitis
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) CZ (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-004888-37 Sponsor Protocol Number: FFR111158 Start Date*: 2016-08-03
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A Pilot, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multicentre Study to Evaluate the Efficacy and Safety of Once-daily Intranasal Administration of Fluticasone Furoate Nasal Spr...
    Medical condition: Irritant (non-allergic) rhinitis
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-006465-16 Sponsor Protocol Number: rhGH in MS Start Date*: Information not available in EudraCT
    Sponsor Name:University of Leipzig
    Full Title: Pilot trial of recombinant human growth hormone for remyelination in multiple sclerosis
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063399 Relapsing-remitting multiple sclerosis LLT
    9.1 10063400 Secondary progressive multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-001560-19 Sponsor Protocol Number: CSCC-ASC2 Start Date*: 2015-06-29
    Sponsor Name:Department of Cardiology, Rigshospitalet
    Full Title: Allogeneic adipose tissue-derived stromal/stem cell therapy in patients with ischemic heart disease and heart failure
    Medical condition: Ischemic heart disease and heart failure
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004849 10019279 Heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Ongoing)
    Trial results: View results
    EudraCT Number: 2018-000230-35 Sponsor Protocol Number: 014-FPO18 Start Date*: 2018-10-17
    Sponsor Name:FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCCS
    Full Title: Phase II study on the combination of trabectedin and olaparib for advanced, platinum-resistant ovarian/tubes and primary of peritoneum cancer. - TROOPS trial (TRabectedin plus Olaparib in advanced ...
    Medical condition: platinum-resistant ovarian carcinoma or Fallopian tubes or primary of peritoneum
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10033131 Ovarian carcinoma LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-000214-71 Sponsor Protocol Number: NAK-03 Start Date*: 2008-07-01
    Sponsor Name:Laboratorios Menarini S.A. (Menarini Group)
    Full Title: Double blind, randomized, placebo-controlled, parallel group study to evaluate the effect of a 4-week treatment with oral doses of MEN15596 in irritable bowel syndrome.
    Medical condition: Irritable Bowel Syndrome.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10023003 Irritable bowel syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) SK (Completed) LV (Completed) DE (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-022253-42 Sponsor Protocol Number: CTU10.041/BRd Start Date*: 2012-02-14
    Sponsor Name:Kantonsspital St. Gallen
    Full Title: An open, multicentric phase II trial to evaluate the efficacy and safety of Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line therapy for patients with relapsed or refracto...
    Medical condition: First relapsed or refractory multiple myeloma (including relapse after high dose chemotherapy followed by autologous stem cell transplantation)
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-002929-19 Sponsor Protocol Number: SCIENCE Start Date*: 2017-01-17
    Sponsor Name:Department of Cardiology, Rigshospitalet
    Full Title: Stem Cell therapy in IschEmic Non-treatable Cardiac disease - SCIENCE
    Medical condition: Ischemic heart disease and heart failure
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004849 10019279 Heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) DK (Completed) SI (Completed) DE (Ongoing) AT (Ongoing) PL (Ongoing)
    Trial results: View results
    EudraCT Number: 2021-003020-32 Sponsor Protocol Number: A011-16 Start Date*: 2022-02-03
    Sponsor Name:Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ, USA
    Full Title: Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo-Controlled for the Treatment of Combined Postcapillary and Precapillary Pulmonary ...
    Medical condition: Combined Postcapillary and Precapillary Pulmonary Hypertension (Cpc-PH) due to Heart Failure with Preserved Ejection Fraction (HFpEF)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037400 Pulmonary hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) FR (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-004281-28 Sponsor Protocol Number: POLARIS2015-003 Start Date*: 2017-01-23
    Sponsor Name:Polaris Pharmaceuticals, Inc.
    Full Title: Randomized, Double-Blind, Phase 2/3 Study in Subjects with Malignant Pleural Mesothelioma to Assess ADI-PEG 20 with Pemetrexed and Cisplatin (ATOMIC-Meso Phase 2/3 Study)
    Medical condition: Advanced malignant pleural mesothelioma (MPM)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10035605 Pleural mesothelioma malignant advanced LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA